Cloud Hosting

LOS ANGELES and MARLBOROUGH, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- RadNet, Inc. (Nasdaq: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, and Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving womens health, have entered into a definitive collaboration to advance the use of artificial intelligence (A.I.) in breast health.

As the world leader in mammography, Hologic will contribute capabilities and insights behind its market-leading hardware and software, and will benefit from access to data produced by RadNets fleet of high-resolution mammography systems, the largest in the nation, to train and refine current and future products based on A.I. RadNet will share data from its extensive network of imaging centers, as well as provide in-depth knowledge of the patient pathway and workflow needs to help make a positive impact across the breast care continuum. The collaboration will enable new joint market opportunities and further efforts to build clinician confidence and develop and integrate new A.I. technologies.

We believe the future of breast health will rely heavily on the integration of A.I. tools, such as our 3DQuorum imaging technology, as well as next generation CAD software, that aid in the early detection of breast cancer, said PeteValenti, Hologics Division President, Breast and Skeletal Health Solutions. We are energized by the opportunities this transformative collaboration with RadNet creates for patients and clinicians alike. Access to data is critical in training and refining A.I. algorithms. With this collaboration, we now have the opportunity to leverage data from the largest fleet of high-resolution mammography systems to develop new tools across the continuum of care, provide workflow efficiencies, and improve patient satisfaction and outcomes.

As part of its collaboration with Hologic, RadNet intends to upgrade its entire fleet of Hologic mammography systems to feature Hologics 3DQuorum imaging technology, powered by Genius AI. This technology works in tandem with Clarity HD high resolution imaging technology to reduce tomosynthesis image volume for radiologists by 66 percent.i Additionally, all of RadNets Hologic systems are anticipated to feature the Genius 3D Mammography exam, the only mammogram clinically proven and FDA approved as superior for all women, including those with dense breasts, compared with 2D mammography alone. ii,iii,iv,v

The collaboration will be bolstered by RadNets recent acquisition of DeepHealth (Cambridge, MA), which uses machine learning to develop software tools to improve cancer detection and provide clinical decision support. Led by Dr. Gregory Sorensen, DeepHealths team of A.I. experts is focused on enabling industry-leading care by providing products that clinicians and patients can trust. In addition, the DeepHealth team will integrate its A.I. tools within the Hologic ecosystem. When seeking a partner and reviewing options amongst all mammography vendors, we selected to integrate our tools with Hologics market-leading technology, said Dr. Sorensen. Hologics systems produce the highest level of spatial resolution in the market. Hologic also has the largest domestic footprint and market share in 3D Mammography systems. This integration will allow the DeepHealth team to train its algorithms for use with the most advanced screening technology possible. As Hologic and RadNet share their respective capabilities and tools, greater efficiency and accuracy can be achieved by our radiologists.

Much like RadNet, Hologic is a highly innovative company and market leader in breast health, said Howard Berger, MD, RadNets Chairman and CEO. When Hologics leading screening technology is paired with RadNets approximately 1.2 million annual screening mammograms, the resulting dataset becomes a powerful tool to train algorithms. We see the future as being transformative for both of our organizations.

We have witnessed how the application of our Genius AI technology platform has improved cancer detection, operational efficiency and clinical decision support across the breast cancer care continuum, said Samir Parikh, Hologics Global Vice President for Research and Development, Breast and Skeletal Health Solutions. We look forward to building upon these advances in collaboration with Dr. Sorensen and the RadNet team to expand the use of machine learning, big data applications and automated algorithms impacting global breast care.

About RadNet, Inc.RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 335 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,600 employees. For more information, visit http://www.radnet.com.

About Hologic, Inc.Hologic, Inc. isan innovative medical technology company primarily focused on improving womens health and well-being through early detection and treatment.For more information on Hologic, visitwww.hologic.com.

The Genius 3D Mammography exam (also known as the Genius exam) is only available on a Hologic 3D Mammography system. It consists of a 2D and 3D image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D image set. There are more than 6,000 Hologic 3D Mammography systems in use in the United States alone, so women have convenient access to the Genius exam. To learn more, visit http://www.Genius3DNearMe.com.

Hologic, 3D Mammography, 3DQuorum, 3Dimensions, Clarity HD, Genius and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking StatementsThis news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic and RadNet expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

Media and Investor Contact RadNet, Inc.:Mark StolperExecutive Vice President & Chief Financial Officer310-445-2800

Media Contact Hologic, Inc.:Jane Mazur508-263-8764 (direct)585-355-5978 (mobile)

Investor Contact Hologic, Inc.:Michael Watts858-410-8588

i Report: CSR-00116

ii Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia Dimensions on screening outcomes. Individual results may vary. The study found an average 41% increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D mammograms acquired with the Hologic 3D Mammography System versus women receiving 2D FFDM mammograms only.

iii Freidewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Carke LD, Greer LN, Miller DP, Conant EF, Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography,JAMAJune 25, 2014.

iv Bernardi D, Macaskill P, Pellegrini M, etal. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.Lancet Oncol.2016 Aug;17(8):1105-13.

v FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005

Read the original:
RadNet and Hologic Announce Collaboration to Advance the Development of Artificial Intelligence Tools in Breast Health - GlobeNewswire